AI Article Synopsis
Article Abstract
Glibenclamide (GB), oral antidiabetic sulfonylurea, is used in the management of diabetes mellitus type II. It suffers from low bioavailability due to low water solubility. This work aimed to enhance the dissolution of GB by formulating the drug as a proniosomes which then improves the pharmacological effect. GB proniosomal formulations were prepared using a slurry method with sucrose as a carrier. The formulations were characterized by particle size, zeta potential, entrapment efficiency %, flow properties of the powder, and in vitro dissolution study. The pharmacological effect was also assessed by determining and measuring the fasting blood glucose level (BGL) before and after the treatment. Formulating GB proniosomes with the slurry method produces a free-flowing powder with a particle size range from 190.050 ± 43.204 to 1369.333 ± 150.407 nm and the zeta potential was above 20 mV (-24 to -58 mV), indicating good stability. The dissolution rate for all formulations was higher than that of the pure drug, indicating the efficiency of the proniosome in enhancing the drug solubility. A significant reduction in the fasting blood glucose level (73 %) was observed in animals treated with proniosomal formulation with no sign of liver damage. In contrast, the pharmacodynamics results show a significant reduction in fasting blood glucose level for animals treated with proniosomes compared to a 17.6 % reduction in BGL after treatment with pure drug. Moreover, the histopathological results showed no sign of liver damage that occurred with proniosomal treatment. GB proniosomal formulations is a promising drug delivery system with good therapeutic efficacy and stability.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666557 | PMC |
| http://dx.doi.org/10.1016/j.jsps.2023.101830 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Traditional versus intensive blood glucose control: long-term target range duration and cardiovascular disease risk and all-cause mortality - a real-world cohort study.
Front Endocrinol (Lausanne)
December 2024
Department of Cardiology, Kailuan General Hospital, Tangshan, China.
Objective: For a long time, the dispute about whether improved glycemic control can bring significant benefits has remained unresolved. We aimed to investigate the association of time spent in different fasting glucose target ranges with cardiovascular risk and all-cause mortality in a population with type 2 diabetes (T2DM).
Method: A total of 3460 T2DM patients in the Kailuan cohort were included in this study.
The association between triglyceride-glucose index and neutrophil-lymphocyte ratio and all-cause mortality in the general US population: NHANES 2001-2018.
Front Endocrinol (Lausanne)
December 2024
Department of Gastric and Colorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China.
Background: The association between the triglyceride-glucose (TyG) index and mortality in the general population remains controversial, with inconsistent findings across studies.
Objective: This study aims to investigate the relationship between the TyG index and mortality in the U.S.
[Association of tumor necrosis factor related apoptosis inducing ligand (TRAIL) gene polymorphism with susceptibility to diabetes periodontitis].
Shanghai Kou Qiang Yi Xue
October 2024
Department of Stomatology, Hengshui Municipal People's Hospital. Hengshui 053000, Hebei Province, China. E-mail:
Purpose: To explore the association between tumor necrosis factor-associated apoptosis-inducing ligand (TRAIL) gene polymorphism and susceptibility to diabetic periodontitis.
Methods: A total of 150 patients with type 2 diabetes were selected from September 2022 to September 2023. The patients were divided into combined group(n=50), non-combined group (n=50) and control group (n=50) according to whether they had periodontitis.
Effects of synbiotics surpass probiotics alone in improving type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
Clin Nutr
December 2024
Department of Nutrition and Health, Key Laboratory of Functional Dairy, Co-constructed by Ministry of Education and Beijing Government, China Agricultural University, Beijing 100193, China. Electronic address:
Background And Aims: Combining probiotics and prebiotics in synbiotics may present a synergistic approach to improve type 2 diabetes mellitus (T2DM); however, further evidence is required to establish the comparative efficacy of synbiotics versus probiotics. This study aimed to evaluate the effects of Bifidobacterium animalis subsp. lactis MN-Gup (MN-Gup) and a synbiotic mixture of MN-Gup and galactooligosaccharide (MN-Gup-GOS) on glycemic control in T2DM patients and explore possible mechanisms.
View Article and Find Full Text PDFMass Balance Recovery, Absorption, Metabolism, and Excretion of Elinzanetant in Healthy Human Volunteers and in vitro Biotransformation.
Eur J Drug Metab Pharmacokinet
December 2024
Preclinical Development-Drug Metabolism and Pharmacokinetics, Bayer AG, Berlin, Germany.
Background: Elinzanetant is a dual neurokinin-1,3 receptor antagonist in development for the treatment of menopausal vasomotor symptoms. The objectives of these studies were to characterize the mass balance and biotransformation of elinzanetant.
Methods: In the clinical evaluation, whole blood, plasma, urine, and feces were collected from healthy fasted male volunteers (n = 6) following a single dose of 120 mg [C]-elinzanetant oral suspension for analysis of total radioactivity and metabolite profiling.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!